Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating)'s stock price fell 5.6% during trading on Thursday . The company traded as low as $6.41 and last traded at $6.89. 113,555 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,687,739 shares. The stock had previously closed at $7.30.
Wall Street Analyst Weigh In
A number of research firms recently commented on ESPR. Morgan Stanley boosted their target price on Esperion Therapeutics from $7.00 to $9.00 and gave the stock an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com upgraded Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.17.
Get Esperion Therapeutics alerts:Esperion Therapeutics Trading Down 5.5 %
The firm has a market cap of $508.42 million, a PE ratio of -1.47 and a beta of 0.23. The stock's 50 day moving average price is $6.74 and its 200 day moving average price is $6.96.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $0.12. The company had revenue of $18.98 million for the quarter, compared to analyst estimates of $19.83 million. Analysts forecast that Esperion Therapeutics, Inc. will post -3.65 earnings per share for the current year.Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $13,067,000. Wasatch Advisors Inc. lifted its holdings in Esperion Therapeutics by 27.6% in the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock valued at $37,804,000 after buying an additional 1,761,117 shares during the period. Millennium Management LLC lifted its holdings in Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock valued at $17,212,000 after buying an additional 1,457,952 shares during the period. Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 7,991.8% in the third quarter. Two Sigma Advisers LP now owns 1,084,300 shares of the biopharmaceutical company's stock valued at $7,265,000 after purchasing an additional 1,070,900 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Esperion Therapeutics in the second quarter valued at approximately $5,372,000. Institutional investors own 85.87% of the company's stock.
Esperion Therapeutics Company Profile
(Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Read More
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.